Tomasz Kuzniar, MD
Pulmonary Disease · Evanston, ILNPI 1114905171
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $81,560 of the $97,944 with a category attached, or 83.3%. Lilly USA, LLC accounts for 94.5% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $94,467, more than ten times the $63 reported in 2019. Among pulmonary disease clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 133 payments — averaging $736.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$93K
- GE HealthCare$3K
- Verathon Inc.$875
- Ambu A/s$550
- Advanced Respiratory, Inc$360
- Inogen, Inc.$239
- plus $785 from 10 others
What the payments were for
- Consulting fees$10,89111%
- Speaking & faculty fees$81,56083%
- Travel & lodging$3,5634%
- Food & beverage$1,9052%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 94 | $92,582 |
| GE HealthCare | 3 | $2,553 |
| Verathon Inc. | 1 | $875 |
| Ambu A/s | 1 | $550 |
| Advanced Respiratory, Inc | 1 | $360 |
| Inogen, Inc. | 10 | $239 |
| Regeneron Healthcare Solutions, Inc. | 8 | $225 |
| Boehringer Ingelheim | 5 | $153 |
| Pulmonx Corporation | 1 | $144 |
| AstraZeneca | 3 | $143 |
| Sanofi | 1 | $28 |
| Resmed Corp | 1 | $26 |
| Philips North America LLC | 1 | $23 |
| Breas Medical, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $14 |
| GSK | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPBOUND$82,099
- Bronchoscope$875
- Life 2000 Ventilation System$360
- ZEPHYR DELIVERY CATHETER$144
- ZEPHYR ENDOBRONCHIAL VALVE$144
- PULMONX CHARTIS TABLET CONSOLE$144
- CHARTIS CATHETER$144
- BREZTRI$102
- AIRSUPRA$102
- TEZSPIRE$102
How this compares
$97,944 in reported general payments places this provider in the 95th percentile of 539 pulmonary disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 38 | $487,245 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 155 | $149,200 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 258 | $143,904 |
| Pirfenidone | 46 | $35,888 |
| Spiriva HandihalerTiotropium Bromide | 40 | $35,545 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 49 | $33,814 |
| Incruse ElliptaUmeclidinium Bromide | 66 | $28,525 |
| Breo ElliptaFluticasone/Vilanterol | 71 | $28,075 |
| Spiriva RespimatTiotropium Bromide | 27 | $21,340 |
| Advair HfaFluticasone Propion/Salmeterol | 23 | $10,965 |
| SymbicortBudesonide/Formoterol Fumarate | 38 | $9,988 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $8,241 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 45 | $7,634 |
| Advair DiskusFluticasone Propion/Salmeterol | 26 | $6,469 |
| Fluticasone-Salmeterol HfaFluticasone Propion/Salmeterol | 12 | $5,521 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $153 | $542,399114 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta | $11 | $349,705550 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $143 | $18,22951 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 539 pulmonary disease providers in Illinois.
Other pulmonary disease in Evanston
- Shashi BellamEvanston$54K
- Sarah GrayEvanston$30K
- Douglas HogarthChicago$2.9M
- Steven WhiteChicago$970K
- Momen WahidiChicago$779K
- Septimiu MurguChicago$633K
- Ayodeji AdegunsoyeChicago$561K
- Kristopher McDonoughJoliet$461K
- Ravi KalhanChicago$375K
- Brian GaribaldiChicago$356K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.